Published in Intensive Care Med on July 01, 1994
Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother (1998) 1.15
Enhanced killing of antibiotic-resistant bacteria enabled by massively parallel combinatorial genetics. Proc Natl Acad Sci U S A (2014) 0.85
Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates. Can J Infect Dis (1997) 0.80
Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics. Can J Infect Dis (1998) 0.76
Clavulanic acid, a novel inhibitor of beta-lactamases. Antimicrob Agents Chemother (1978) 4.27
New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) (1990) 4.04
Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Antimicrob Agents Chemother (1984) 2.71
Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases. Antimicrob Agents Chemother (1986) 2.63
Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Antimicrob Agents Chemother (1986) 2.48
Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes. Antimicrob Agents Chemother (1986) 2.39
Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother (1989) 1.59
A 10-year survey of clinically significant blood culture isolates and antibiotic susceptibilities from adult patients with hematological diseases at a major Swedish hospital. Scand J Infect Dis (1990) 1.53
Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens. Antimicrob Agents Chemother (1981) 1.49
Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother (1989) 1.47
Penetration of piperacillin into bronchial mucosa and sputum. Thorax (1981) 1.36
Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents. Antimicrob Agents Chemother (1991) 1.35
Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). Diagn Microbiol Infect Dis (1990) 1.27
Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors. Rev Infect Dis (1987) 1.23
Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother (1992) 1.15
Aspiration pneumonia. Rev Infect Dis (1991) 1.08
Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn Microbiol Infect Dis (1990) 1.06
Early synergistic interaction between semisynthetic penicillins and aminoglycosidic aminocyclitols against Enterobacteriaceae. Antimicrob Agents Chemother (1983) 0.97
Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother (1993) 0.94
Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group. Antimicrob Agents Chemother (1993) 0.92
Therapy of soft tissue infections with piperacillin/tazobactam. J Antimicrob Chemother (1993) 0.92
Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli. Antimicrob Agents Chemother (1990) 0.89
In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases. Chemotherapy (1990) 0.87
Carbapenems: special properties contributing to their activity. Am J Med (1985) 0.86
Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates. J Chemother (1990) 0.85
The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia. J Antimicrob Chemother (1993) 0.82
Therapy of mixed anaerobic-aerobic infections. Lessons from studies of intra-abdominal sepsis. Am J Med (1985) 0.80
Antimicrobial resistance: implications for antibiotic use. Am J Med (1986) 0.76
[Epidemiologic study of pathogens causing nosocomial infections]. J Formos Med Assoc (1990) 0.75
Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria. J Formos Med Assoc (1991) 0.75
In vitro and in vivo efficacy of YTR-830H and piperacillin combinations versus beta-lactamase-producing bacteria. J Chemother (1989) 0.75
Evolution of beta-lactamase inhibitors. Surg Gynecol Obstet (1991) 0.75
The frequency of bacterial pathogens in infections potentially preventable by antimicrobial prophylaxis. Scand J Infect Dis Suppl (1990) 0.75